𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

✍ Scribed by Pratap Chokka; Mark Legault

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
131 KB
Volume
25
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effectiveness and tolerability of paroxe
Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea
✍ Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 127 KB πŸ‘ 1 views

## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled

How long should a trial of escitalopram
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
✍ David S. Baldwin; Dan J. Stein; Ornah T. Dolberg; Borwin Bandelow πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 130 KB πŸ‘ 2 views

## Abstract ## Objective To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo‐controlled trials (RCTs) and to infer the optimal duration of initial

An open trial of buspirone in the treatm
An open trial of buspirone in the treatment of attention-deficit disorder
✍ Helmut Niederhofer πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 48 KB

## Abstract ## Objective Medications such as clonidine have been shown to facilitate calming, to enhance frustration tolerance, and to reduce aggression in attention deficit disorder (ADD) patients. The use of buspirone was studied as an alternative because of its longer excretion half‐life, decre